These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Designing better drugs: predicting cytochrome P450 metabolism. de Groot MJ Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528 [TBL] [Abstract][Full Text] [Related]
25. Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties. Huang G; Nimczick M; Decker M Arch Pharm (Weinheim); 2015 Aug; 348(8):531-40. PubMed ID: 25941009 [TBL] [Abstract][Full Text] [Related]
26. Selective optimization of side activities: another way for drug discovery. Wermuth CG J Med Chem; 2004 Mar; 47(6):1303-14. PubMed ID: 14998318 [No Abstract] [Full Text] [Related]
28. Selective binding of small molecules to DNA: application and perspectives. Wang B; Tan J; Zhu L Colloids Surf B Biointerfaces; 2010 Aug; 79(1):1-4. PubMed ID: 20447811 [TBL] [Abstract][Full Text] [Related]
29. PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem. Canny SA; Cruz Y; Southern MR; Griffin PR Bioinformatics; 2012 Jan; 28(1):140-1. PubMed ID: 22084255 [TBL] [Abstract][Full Text] [Related]
30. On the parabolic relationship between biological activity and hydrophobicity of drugs: transport or protein binding? Franke R Experientia Suppl; 1976; 23():25-30. PubMed ID: 954940 [No Abstract] [Full Text] [Related]
31. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity. Dimova D; Hu Y; Bajorath J J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678 [TBL] [Abstract][Full Text] [Related]
32. Adverse reactions to drugs and their physico-chemical properties. Lewis JG Postgrad Med J; 1981 Nov; 57(673):679-82. PubMed ID: 7041105 [TBL] [Abstract][Full Text] [Related]
33. Fragment-based drug design: how big is too big? Hajduk PJ J Med Chem; 2006 Nov; 49(24):6972-6. PubMed ID: 17125250 [TBL] [Abstract][Full Text] [Related]
35. The Role of Target Binding Kinetics in Drug Discovery. Guo D; Heitman LH; IJzerman AP ChemMedChem; 2015 Nov; 10(11):1793-6. PubMed ID: 26506404 [TBL] [Abstract][Full Text] [Related]
36. NMR in drug discovery. Pellecchia M; Sem DS; Wüthrich K Nat Rev Drug Discov; 2002 Mar; 1(3):211-9. PubMed ID: 12120505 [TBL] [Abstract][Full Text] [Related]
37. Drug targeting via retrometabolic approaches. Bodor N; Buchwald P Pharmacol Ther; 1997; 76(1-3):1-27. PubMed ID: 9535166 [TBL] [Abstract][Full Text] [Related]
38. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. Dobson PD; Patel Y; Kell DB Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901 [TBL] [Abstract][Full Text] [Related]
39. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect. Kenakin T ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052 [TBL] [Abstract][Full Text] [Related]
40. Inhibitor focusing: direct selection of drug targets from proteomes using activity-based probes. Nomanbhoy TK; Rosenblum J; Aban A; Burbaum JJ Assay Drug Dev Technol; 2003 Feb; 1(1 Pt 2):137-46. PubMed ID: 15090140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]